TY - JOUR
T1 - Therapeutic outcomes of 68 cases with oropharyngeal squamous cell carcinoma referring to UICC version 7 and 8
AU - Tamae, Akihiro
AU - Sato, Masanobu
AU - Yamamoto, Hidetaka
AU - Noda, Teppei
AU - Nishiyama, Kazuo
AU - Nakashima, Koichiro
AU - Yasumatsu, Ryuji
N1 - Publisher Copyright:
© 2020, Japan Society for Head and Neck Cancer. All rights reserved.
PY - 2020
Y1 - 2020
N2 - We retrospectively reviewed the records of 68 patients with oropharyngeal squamous cell carcinoma who had undergone initial treatment in the Department of Otolaryngology, Head and Neck Surgery, Hamanomachi Hospital between 2009 and 2017. We compared therapeutic outcomes of p16-positive with p16-negative cases, referring to Unio Internationalis Contra Cancrum（UICC）diagnostic criteria version 7 and 8. Of 68（58.5％）patients, 38 were diagnosed as p16-positive. The 3-year disease-specific survival rate of all patients, p16-positive, and p16-negative patients were 78.5％, 74.1％, and 84.7％, respectively. Referring to UICC version 8, the 3-year disease-specific survival rate（3DSS）of p16-negative patients in each clinical stage was stage Ⅱ: 100％, stageⅢ: 66.7％, and stage Ⅳa: 70.6％, whereas 3DSS of p16-positive patients was stage I: 93.8％, stageⅡ: 83.3％, stageⅢ: 77.1％, and stage Ⅳ: 0％.
AB - We retrospectively reviewed the records of 68 patients with oropharyngeal squamous cell carcinoma who had undergone initial treatment in the Department of Otolaryngology, Head and Neck Surgery, Hamanomachi Hospital between 2009 and 2017. We compared therapeutic outcomes of p16-positive with p16-negative cases, referring to Unio Internationalis Contra Cancrum（UICC）diagnostic criteria version 7 and 8. Of 68（58.5％）patients, 38 were diagnosed as p16-positive. The 3-year disease-specific survival rate of all patients, p16-positive, and p16-negative patients were 78.5％, 74.1％, and 84.7％, respectively. Referring to UICC version 8, the 3-year disease-specific survival rate（3DSS）of p16-negative patients in each clinical stage was stage Ⅱ: 100％, stageⅢ: 66.7％, and stage Ⅳa: 70.6％, whereas 3DSS of p16-positive patients was stage I: 93.8％, stageⅡ: 83.3％, stageⅢ: 77.1％, and stage Ⅳ: 0％.
UR - http://www.scopus.com/inward/record.url?scp=85084803630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084803630&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.46.59
DO - 10.5981/jjhnc.46.59
M3 - Article
AN - SCOPUS:85084803630
SN - 1349-5747
VL - 46
SP - 59
EP - 63
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
IS - 1
ER -